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Objective. Rituximab, a type I anti-CD20 mono-
clonal antibody (mAb), induces incomplete B cell deple-
tion in some patients with rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE), thus contrib-
uting to a poor clinical response. The mechanisms of
this resistance remain elusive. The purpose of this
study was to determine whether type II mAb are more
efficient than type I mAb at depleting B cells from RA
and SLE patients, whether internalization influences
the efficiency of depletion, and whether Fcg receptor
type IIb (FcgRIIb) and the B cell receptor regulate this
internalization process.
Methods. We used an in vitro whole blood B cell–
depletion assay to assess the efficiency of depletion,
flow cytometry to study cell surface protein expression,
and surface fluorescence–quenching assays to assess
rituximab internalization, in samples from patients
with RA and patients with SLE. Paired t-test or
Mann-Whitney U test was used to compare groups, and
Spearman’s rank correlation test was used to assess
correlation.
Results. We found that type II mAb internalized
significantly less rituximab than type I mAb and depleted
B cells from patients with RA and SLE at least 2-fold
more efficiently than type I mAb. Internalization of rituxi-
mab was highly variable between patients, was regulated
by FcgRIIb, and inversely correlated with cytotoxicity in
whole blood B cell–depletion assays. The lowest levels of
internalization were seen in IgD– B cells, including post-
switched (IgD– CD271) memory cells. Internalization of
type I anti-CD20 mAb was also partially inhibited by anti-
IgM stimulation.
Conclusion. Variability in internalization of rituxi-
mab was observed and was correlated with impaired B
cell depletion. Therefore, slower-internalizing type II mAb
should be considered as alternative B cell–depleting
agents for the treatment of RA and SLE.
B cell–targeted monoclonal antibodies (mAb)
are increasingly being explored for use in the treatment
of autoimmune diseases such as rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE). Rituxi-
mab (RTX), a chimeric anti-CD20 mAb, is licensed for
the treatment of RA and is used extensively off-label for
the treatment of refractory SLE. However, RTX indu-
ces incomplete B cell depletion in some individuals with
RA (1) and SLE (2), which may at least partly explain
the poor clinical response noted in some individuals
(3,4). A long duration of B cell depletion in RA (using
an extra dose of RTX) (5) and SLE patients is associ-
ated with better clinical response (6). Hence, enhancing
B cell depletion may improve treatment efficacy, and
understanding the mechanisms of resistance in RA and
SLE is of clear clinical importance. B cell–depletion
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studies in lupus-prone mice suggest disease-specific me-
chanisms of resistance to anti-CD20 mAb (7), but the
precise mechanisms of resistance to RTX in patients
with RA and SLE remain elusive.
Administration of anti-CD20 mAb can evoke 3
main cytotoxic effector mechanisms, antibody-dependent
cell-mediated cytotoxicity (ADCC), complement-dependent
cytotoxicity (CDC), and direct cell death (8). The associa-
tion between Fcg receptor type IIIa (FcgRIIIa) genotype
and clinical response and/or the degree of B cell depletion
in RA (9) and SLE (10) suggests that the ADCC-type
FcgR-dependent systems (including antibody-dependent
cellular phagocytosis) are the main RTX effector mecha-
nisms in vivo, in both RA and SLE, as previously noted
for some B cell malignancies (11–13).
Anti-CD20 mAb can be categorized into 2 types
based on whether they redistribute CD20 into lipid rafts
and consequently evoke different effector mechanisms
(8,14). Type I mAb include RTX, ofatumumab (2F2, a fully
human IgG1), and ocrelizumab (a humanized IgG1). Both
ofatumumab and ocrelizumab have been shown to be effec-
tive in treating patients with RA (15,16). Type II mAb
include tositumomab (anti-B1, a mouse IgG2a) and obinu-
tuzumab (GA101, a glycoengineered human IgG1). Type
II mAb have been shown to be more efficient than type I at
depleting B cells in preclinical models (17) and in patients
with B cell malignancies (18), resulting in improved clinical
efficacy in chronic lymphocytic leukemia (19). However,
whether type II mAb are more effective at depleting B cells
from patients with RA and SLE is not known.
The improved efficacy of type II mAb is attributed
to the observation that normal and malignant B cells inter-
nalize type I mAb more rapidly than type II, a mechanism
regulated by the inhibitory Fcg receptor IIb (FcgRIIb) on
B cells (20). Internalization of mAb reduces the ability to
activate FcgR-dependent ADCC functions (21), including
phagocytosis (20,22), and so is thought to be detrimental for
target-cell depletion, with the expression of FcgRIIb on tar-
get lymphoma cells being associated with a poor clinical
response to RTX (20,23). However, whether similar resist-
ancemechanisms are operant in RA and SLE is not known.
In autoimmune conditions, internalization of B
cell–targeted antigen–mAb-complexes may have a bene-
ficial immunomodulatory effect, as discussed elsewhere
(24). For example, epratuzumab, an anti-CD22 mAb, is
rapidly internalized after binding to its target antigen
CD22, and so anti-CD22 mAb–conjugated toxins are
used to treat B cell malignancies (25). Unconjugated
anti-CD22 mAb may have utility in autoimmune situa-
tions by facilitating endocytosis of CD22 and modulat-
ing B cell receptor (BCR) signaling (26), in addition to
eliciting modest ADCC (27). Epratuzumab appears to
be effective in SLE (28). B cells from patients with SLE
likely internalize anti-CD22 mAb (29); whether FcgRIIb
regulates this internalization is not known.
In this study, we found that the slower-internalizing
type II anti-CD20 mAb depleted B cells from patients with
RA and SLE more efficiently than either type I anti-CD20
or anti-CD22 mAb and that internalization influenced the
efficiency of depletion. We also found that the extent of
internalization of rituximab was highly variable between
patients, was regulated by FcgRIIb, and was inversely
correlated with its cytotoxicity in whole blood B cell–
depletion assays. Blocking of FcgRIIb inhibited the inter-
nalization of type I anti-CD20 mAb, with variable levels of
internalization noted between different B cell subpopula-
tions; being least for postswitched (IgD–CD271) memory
cells and IgD– cells. Internalization of type I anti-CD20,
but not anti-CD22, mAb was partially inhibited by stimu-
lation with anti-IgM, which suggests independent roles
for the BCR and FcgRIIb in facilitating the internaliza-
tion of type I mAb.
PATIENTS AND METHODS
Patients and healthy blood donors. Ethical approval
for the study was obtained from the National Research Ethics
Committee. Whole blood samples from all participants were ob-
tained with their informed consent, adhering to the Declaration
of Helsinki.
Demographic features of the RA and SLE patients are
summarized in Supplementary Tables 1 and 2, respectively,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39167/abstract. The median
age of the 3 study groups was 31 years (range 22–60 years) in the
healthy controls, 52 years (range 24–79 years) in the RA patients,
and 39 years (range 21–76 years) in the SLE patients. All RA
patients were positive for rheumatoid factor and/or anti–cyclic cit-
rullinated peptide antibodies. Peripheral blood was collected into
tubes containing lithium heparin. Peripheral blood mononuclear
cells (PBMCs) were separated using Ficoll-Paque density-gradient
centrifugation, and B cells were isolated from the PBMCs by nega-
tive selection using either a humanB cell enrichment kit (StemCell
Technologies) or humanB cell isolation kit II (Miltenyi Biotec).
Antibodies and reagents. AT10, which binds both
FcgRIIa and FcgRIIb (30), was produced in-house. Rituximab
was a gift from the Southampton General Hospital Pharmacy,
and tositumomab was a gift from Prof T. Illidge (University of
Manchester, Manchester, UK). Glycosylated GA101 with an
unmodified Fc portion (GA101Gly) and ofatumumab were pro-
duced in-house from patented published sequences in Chinese
hamster ovary or 293F cells; therefore, their carbohydrate
structures may differ from mAb in clinical use. Alexa Fluor
488 and anti–Alexa Fluor 488 were purchased from Invitrogen.
The mAb were labeled with Alexa Fluor 488 according to the
manufacturer’s (Invitrogen) instructions.
Flow cytometry. The following fluorochrome-conjugated
mAb (all from Becton Dickinson) were used for flow cyto-
metry: CD3 (allophycocyanin), CD19 (phycoerythrin [PE]–Cy7
or PerCP–Cy5.5), CD20 (fluorescein isothiocyanate), CD32 (PE),
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CD45 (PE), and IgD (Brilliant Violet 421). Flow cytometry was
performed using a Becton Dickinson LSRFortessa cell analyzer.
Lymphocyte populations were identified using forward- and side-
scatter characteristics and CD45 positivity. B cells were identified
as CD191 or CD201 and T cells as CD31. To account for inter-
experimental variation, the mean fluorescence intensity (MFI) of
CD20 and FcgRIIb was determined as the ratio of the MFI of
CD20/FcgRIIb to the MFI of the isotype control.
Whole blood B cell–depletion assay. The whole blood
B cell–depletion assay was performed as described previously
(31). Briefly, 100 ml of freshly drawn whole blood was incu-
bated in the presence or absence of mAb at 378C in an atmos-
phere of 5% CO2. Samples were harvested after 24 hours and
stained with anti-CD3, anti-CD19, and anti-CD45 and then
incubated for another 30 minutes before lysing the red blood
cells with BD PharmLyse. Ten thousand events were acquired
in the lymphocyte gate per sample, and the data were analyzed
by flow cytometry using FlowJo software using the protocol
shown in Figure 1A. The percentage of B cell depletion with
mAb was defined as the cytotoxicity index (CTI) and was
determined using the following formula: CTI of mAb5 100 –
[(100/B cell:T cell ratio in sample without antibody) 3 (B
cell:T cell ratio in sample with antibody)]. The percentage B
cell depletion in the sample without antibody is set at 0. The
mean values for triplicate wells were used to calculate the CTI.
Surface fluorescence–quenching assay. The surface
fluorescence–quenching assay was performed as described pre-
viously (22). Briefly, 2–4 3 105 B cells were incubated with
Alexa Fluor 488–labeled mAb in a volume of 5 mg/ml at 378C
for 6 hours. As we had observed differences in the ability of dif-
ferent IgG isotypes to activate FcgRIIb (20), all mAb used were
either human or mouse IgG1, which give equivalent activity in
internalization assays with anti-CD20 mAb (24). Samples were
then harvested, washed twice, and incubated for 30 minutes at
48C with PE–Cy7–labeled anti-CD19 in the presence or absence
of anti–Alexa Fluor 488 quenching antibody (Invitrogen). After
washing, samples were analyzed by flow cytometry.
We investigated internalization in the following B cell sub-
populations: naive (IgD1CD27–), preswitched (IgD1CD271),
postswitched (IgD–CD271), and double-negative (IgD–CD27–)
cells. Samples were stained with PE–Cy7–labeled anti-CD19,
BV421-labeled IgD, or PE-labeled CD27 after incubation with
Alexa Fluor 488–labeled mAb.
The effect of FcgRIIb on internalization of mAb was
investigated by comparing the MFI of FcgRIIb in samples
with and those without prior incubation with AT10 at 50 mg/ml
for 30 minutes before the addition of Alexa Fluor 488–labeled
mAb. The effect of B cell activation on internalization was
investigated by stimulating isolated B cells with anti-IgM
F(ab0)2 at 25 mg/ml for 30 minutes or for 6 hours before incu-
bating with Alexa Fluor 488–labeled mAb.
Statistical analysis. Statistical analyses were per-
formed with GraphPad Prism software version 5.0. Paired-t
test or Mann-Whitney U test was used to compare groups as
appropriate. Spearman’s rank correlation r2 was used to ana-
lyze correlations between parameters.
RESULTS
Double the efficiency of B cell depletion by type II
mAb versus type I mAb. The autologous whole blood
B cell–depletion assay is a comprehensive method for
assessing mAb cytotoxicity in vitro, as it accounts for all
3 effector mechanisms evoked by mAb: ADCC, CDC,
and direct cell death. This assay was previously used to
show that type II mAb are more efficient at lysing B
cells from healthy control subjects and from patients
with B cell malignancies (18,31). However, whether type
II mAb are more efficient at lysing B cells from patients
with autoimmune disease is not known.
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Figure 1. Whole blood B cell–depletion assay. A, Whole blood sam-
ples were incubated with or without rituximab (RTX) or glycosylated
GA101 with an unmodified Fc portion (GA101Gly) for 24 hours, and
the percentage of B cell death was determined by flow cytometry.
Ten thousand events gated on lymphocytes were acquired per sam-
ple. B cells were identified as CD191 and T cells as CD31. B, Cyto-
toxicity (percentage B cell depletion) of RTX was significantly lower
than that of GA101Gly in samples from healthy controls (n5 9),
patients with rheumatoid arthritis (RA; n5 26) and patients with
systemic lupus erythematosus (SLE; n5 50). Cytotoxicity achieved by
both RTX and GA101Gly was significantly lower in SLE patients
than in healthy controls or in RA patients. Data are shown as box
plots. Each box represents the interquartile range. Lines inside the
boxes represent the median. Whiskers represent the range. **5P, 0.005;
***5P, 0.0001.
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Since SLE patients often have lymphopenia, mak-
ing extensive assays difficult, we initially determined the
optimal concentration of mAb (0.01, 0.1, 1, and 10 mg/ml)
required for the assay using blood from healthy controls.
In these assays, we used nonglycomodified versions of
GA101 to directly assess the effects of type I versus type II
mAb without the influence of afucosylation. Independent
experiments were performed in whole blood samples from
4 healthy control subjects. The mean percentage of cell
death was used to assess the cytotoxicity of the mAb and
to determine the optimum dose. We found that GA101Gly
was significantly more efficient at lysing B cells than rituxi-
mab was in all 4 samples at all 4 concentrations tested (see
Supplementary Figure 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.39167/abstract). Therefore, we used 1 mg/ml for
subsequent experiments.
The cytotoxicity index from the autologous whole
blood B cell–depletion assay (1 mg/ml) was calculated in
whole blood samples from 9 healthy control subjects, 26
patients with RA, and 50 patients with SLE (Figure 1B).
GA101Gly (type II mAb) was found to be significantly
more efficient than RTX (type I mAb) at lysing B cells in
vitro in samples from all study groups. The mean6SD
CTI for GA101Gly versus RTX was 636 11 versus
366 18 in healthy controls (P5 0.005), 546 16 versus
276 16 in RA patients (P , 0.0001), and 386 15 versus
176 12 in SLE patients (P , 0.0001). There was no sig-
nificant difference between the CTI for RTX in healthy
controls and RA patients, whereas the CTI for RTX was
significantly lower in SLE patients as compared with healthy
controls (P5 0.008) and RA (P5 0.01). Similarly, there
was no significant difference in the CTI for GA101Gly
between healthy controls and RA patients, whereas it was
significantly lower in SLE patients as compared with healthy
controls (P5 0.0006) and with RA patients (P , 0.0001)
(Figure 1B). The median ratio of the CTI for GA101Gly to
the CTI for RTX was 1.5, 1.7, and 2.5, for healthy controls,
RA patients, and SLE patients, respectively.
We did not find a correlation between the CTI
for RTX and the distribution of relative frequencies of
B cell subpopulations (data not shown and Supplemen-
tary Table 3, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.
39167/abstract.) or serum complement C3 levels (data
not shown). Taken together, these results suggested that
type II mAb are more effective at depleting B cells in
each subset of study subjects and that B cells from SLE
patients are less susceptible to lysis by RTX and by
GA101Gly, indicating an inherent resistance mechanism.
Next, we wanted to investigate whether the differ-
ence in the B cell–lysing potential of RTX and GA101Gly
was also applicable to additional type I and type II mAb.
We therefore compared the CTI of 2 other mAb: ofatumu-
mab (2F2) and tositumomab (B1), representing type I and
type II mAb, respectively (Figure 2A). Again, we found
that type II mAb were significantly more efficient than type
I mAb at lysing B cells in all samples examined from
patients with RA (n5 3) and SLE (n5 10). We noted a
significant hierarchy in the efficiency of CTI of the mAb,
with GA101Gly.B1.2F2.RTX and with a .2-fold dif-
ference in the CTIs for GA101Gly versus 2F2 (Figure 2A).
As anti-CD22 mAb have also been reported to
deplete B cells, albeit weakly (27), we examined their
activity in the assay. We found that the CTI for anti-
CD22 mAb was found to be significantly lower than
that for anti-CD20 mAb, with a CTI hierarchy of anti-
CD22 ,RTX,GA101Gly (n5 4) (Figure 2B). This may
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Figure 2. Efficiency of B cell lysis by type I monoclonal antibody
(mAb) as compared with type II mAb and with anti-CD22 mAb. A,
Whole blood samples were incubated with or without 1 mg/ml of
either rituximab (RTX; IgG1), ofatumumab (2F2; IgG1), tositumo-
mab (B1; mouse IgG2a), or glycosylated GA101 with an unmodified
Fc portion (GA101Gly; IgG1). After 24 hours, the percentage of B
cell death was measured by flow cytometry. The cytotoxicity of type I
and type II mAb was compared in patients with rheumatoid arthritis
(n5 3) and systemic lupus erythematosus (SLE; n5 10). Type I
mAb lysed B cells less efficiently than did type II mAb, with a cyto-
toxicity index for RTX, 2F2,B1,GA101Gly. Values are the mean
of triplicate wells. Each line represents an individual sample. B, In
SLE patients (n5 4), the cytotoxicity index of anti-CD22mAb was
significantly lower than that of RTX and GA101Gly. *5P , 0.05;
**5P , 0.005; ***5P , 0.0001.
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be at least partly due to the differences in internalization of
the mAb, as noted previously for B cell malignancies (24).
Both B cell–intrinsic and B cell–extrinsic factors
may account for the apparent resistance of SLE B cells to
depletion. Malignant B cell expression of CD20 (32) and
FcgRIIb (20) correlated with susceptibility to deletion by
anti-CD20 mAb; however, we did not find a correlation
between the expression of CD20 and FcgRIIb or
between their relative expression (ratio of the MFI of
CD20 to the MFI of FcgRIIb) and the CTI for RTX or
GA101Gly in all groups examined (data not shown). This
may reflect the relatively small difference in B cell expres-
sion of CD20 and FcgRIIb between these RA and SLE
study patients (data not shown), in contrast to that
reported for patients with B cell malignancies (20,32).
Efficiency of depletion influenced by internal-
ization of rituximab. Given the large variability in de-
pletion afforded by RTX in SLE and a superior efficacy
of type II mAb in the whole blood B cell–depletion assays,
we next examined whether internalization of mAb might
explain the greater resistance of SLE B cells to depletion.
Internalization was assessed using the surface fluores-
cence–quenching assay using isolated B cells from 5
healthy controls, 16 patients with RA, and 22 patients
with SLE. In all groups, a significantly greater percentage
of GA101Gly than RTX was accessible on the cell surface.
The median percentage of surface-accessible mAb after 6
hours of incubation for GA101Gly versus RTX in the
healthy controls, RA patients, and SLE patients was
67 versus 57, 69 versus 55 (P, 0.005), and 74 versus 47 (P
, 0.005), respectively (Figure 3A). Thus, internalization
of mAb was a notable feature of B cells from healthy con-
trols as well as from patients with RA and SLE.
Interestingly, we noted a correlation between
surface-accessible RTX and the CTI for RTX (Spear-
man’s r25 0.5, P , 0.05) (Figure 3B) and between the
relative CTI for GA101Gly and the relative CTI for RTX
(Spearman’s r25 0.6, P , 0.05) in samples from SLE
patients, but not those from healthy controls or RA
patients (data not shown).
The relative potency of RTX compared with
GA101Gly also differed, such that in samples with .65%
surface-accessible RTX (n5 5), the mean difference in
relative potency was 2-fold, whereas in samples with
,40% surface-accessible RTX (n5 5), the mean differ-
ence in relative potency was 4-fold (Figure 3C). We found
no significant correlations between surface-accessible
GA101Gly and the CTI for GA101Gly in all groups exam-
ined (data not shown). The results therefore suggest that
internalization of RTX contributes to its inferior effi-
ciency of depletion, as assessed by whole blood B cell–
depletion assay, in B cells from SLE patients.
FcgRIIb facilitation of rituximab internalization.
RTX internalizes as part of a tripartite complex with
CD20 and FcgRIIb (20), but B cell expression of
FcgRIIb may be altered in SLE (33). We therefore in-
vestigated whether FcgRIIb also regulated the internal-
ization of mAb in samples from RA and SLE patients
and whether FcgRIIb internalized to a greater extent
with RTX than with GA101Gly. Isolated B cells from 3
healthy controls, 9 RA patients, and 9 SLE patients
were incubated for 6 hours in the presence or absence
of 5 mg/ml of mAb. A significant difference in the mean
fluorescence intensity of FcgRIIb (P , 0.005 for each
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Figure 3. Internalization of rituximab (RTX) to a highly variable
extent, impairing its efficiency of depletion. A, Internalization was
assessed by surface fluorescence–quenching assay, which revealed that a
greater percentage of glycosylated GA101 with an unmodified Fc por-
tion (GA101Gly) than RTX was accessible for quenching in samples
from healthy controls (n5 5), rheumatoid arthritis patients (n5 16),
and systemic lupus erythematosus (SLE) patients (n5 22). Each line
represents an individual sample. *5P , 0.05; ***5P , 0.0001. B,
Spearman’s rank correlation analysis showed a significant correlation
between the percentage of surface-accessible RTX and the percentage
of B cell depletion in patients with SLE (n5 22), as assessed by whole
blood B cell–depletion assay. C, The relative cytotoxicity and the ratio of
the cytotoxicity index (CTI) for GA101Gly to the CTI for RTX between
SLE patients with.65% surface-accessible RTX and SLE patients with
,40% surface-accessible RTX was 2-fold and 4-fold, respectively, and
correlated with the percentage of surface-accessible RTX, by Spear-
man’s rank correlation analysis. mAbs5monoclonal andibodies.
2050 REDDY ET AL
comparison) was seen in all 3 groups (Figures 4A and
B), with RTX having the greatest internalization.
We then examined whether blocking FcgRIIb
inhibited internalization in samples from 11 patients with
SLE, with or without prior incubation with AT10 (an
FcgRII-specific mAb) (30). Internalization of both RTX
and GA101Gly was inhibited by AT10. However, accessi-
ble RTX was greater in samples incubated with AT10 as
compared with samples without AT10 (median 61% ver-
sus 51%, respectively) whereas this difference was only
modest for GA101Gly (median 78% versus 74%) (Figure
4C). Intriguingly, despite blocking FcgRIIb, the median
surface-accessible RTX was lower than that of GA101Gly
(61% versus 78%). Although there was no direct correla-
tion between the degree of inhibition of internalization
with AT10 or between the MFI of FcgRIIb and the fold
difference between the CTI for RTX and the CTI for
GA101Gly, we noted that in the 2 samples with the great-
est inhibition of mAb internalization, the CTI for GA101Gly
was .4-fold higher than that for RTX, whereas the mean
for the cohort was a 2-fold difference in CTI between the 2
mAb (data not shown). Thus, FcgRIIb facilitated the inter-
nalization of type I CD20 mAb and reduced the efficiency
of deletion, albeit to a variable extent.
Disparity in internalization of B cell–targeted
mAb. In addition to CD20, mAb targeting other B cell
surface antigens are being explored for use in SLE,
including CD19 (34) and CD22 (28). We therefore in-
vestigated whether the differences in the CTIs for type I
and type II CD20 mAb and anti-CD22 mAb (Figure 2B)
were due to a disparity in internalization and whether
FcgRIIb regulated their internalization. The median
percentages of surface-accessible mAb were 67%, 51%,
73%, 22%, and 76% for anti-CD19, type I anti-CD20
(RTX), type II anti-CD20 (GA101Gly), anti-CD22, and
anti-CD38 mAb, respectively (Figure 5). Furthermore,
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Figure 4. Fcg receptor type IIb (FcgRIIb) regulation of the internal-
ization of rituximab (RTX). A, The mean fluorescence intensity (MFI)
of FcgRIIb was significantly lower in samples incubated with RTX
than in those incubated with glycosylated GA101 with an unmodified
Fc portion (GA101Gly) in all samples from healthy control (HC) sub-
jects (n5 3), rheumatoid arthritis (RA) patients (n5 9), and systemic
lupus erythematosus (SLE) patients (n5 9), suggesting that RTX was
internalized along with FcgRIIb. Each line represents an individual
sample. B, The MFI of FcgRIIb in samples incubated with monoclonal
antibodies (mAb) compared with that in samples without antibodies,
expressed as a percentage of untreated samples, revealed significantly
lower values in samples incubated with RTX as compared with those
incubated with GA101Gly in all 3 study groups. Values are the
mean6 SD. C, Blocking of FcgRIIb using AT10 (an anti-FcgRII
mAb) inhibited the internalization of RTX to a greater extent than
that of GA101Gly in SLE patients (n5 11). Each line represents an
individual sample. *5P, 0.05; **5P, 0.005; ***5P, 0.0001.
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Figure 5. Disparity in the internalization of monoclonal antibodies
(mAb) and inhibition by Fcg receptor type IIb (FcgRIIb). There
was a high rate of internalization of anti-CD22 mAb, as assessed by
the surface fluorescence–quenching assay. Internalization of rituxi-
mab (RTX; a type I anti-CD20 mAb) and, to some extent, anti-
CD19 mAb, showed remarkable variability between samples, whereas
internalization of anti-CD38 mAb and glycosylated GA101 with an
unmodified Fc portion (GA101Gly) was consistently low. Internaliza-
tion of only type I and type II anti-CD20 mAb, but not the other
mAb, was significantly inhibited by anti-FcgRII mAb (AT10). Each
symbol represents an individual sample; horizontal lines show the
median. **5P , 0.005; ***5P , 0.0001.
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similar to our observations in malignant B cells (24), SLE
B cells also displayed a remarkable degree of internaliza-
tion of anti-CD22 mAb, greater than that seen with RTX,
whereas the other mAb (anti-CD19, anti-CD38, and
GA101Gly) were internalized to a lesser degree. In contrast
to the hierarchy of depletion with mAb, with anti-
CD22,RTX,GA101Gly (Figure 2B), we noted a re-
verse hierarchy of the extent of internalization, with anti-
CD22.RTX.GA101Gly. However, only internalization
of anti-CD20 mAb was consistently inhibited by AT10 and
was therefore FcgRIIb-dependent.
Influence of IgD and B cell activation on the in-
ternalization of type I mAb. We next examined whether
there were any differences in internalization between B
cell subpopulations in samples from 5 patients with SLE.
In all cases, postswitched memory cells internalized sig-
nificantly less RTX than did naive, preswitched, and
double-negative cells (P , 0.05 for each comparison)
(Figure 6A). For GA101Gly, a significant difference was
noted between postswitched cells and naive and double-
negative cells before blocking with AT10 and only in
naive cells after blocking with AT10.
B
na
ivepre
-s
po
st-
s
DN
na
ivepre
-s
po
st-
s
DN
na
ivepre
-s
po
st-
s
DN
na
ivepre
-s
po
st-
s
DN
0
20
40
60
80
100
*
* * *
* * *** *
RTX GA101gly
mAb mAb+AT10 mAb mAb+AT10
su
rfa
ce
 a
cc
es
si
bl
e 
m
Ab
s 
(%
)
0
20
40
60
80
100 * *
IgD-IgD+
mAb mAb+AT10 mAb mAb+AT10
RTX GA101gly
su
rfa
ce
 a
cc
es
si
bl
e 
m
Ab
s 
(%
)
0
20
40
60
80
100
0.5   
NT anti-IgM F(ab')2
Time (h)
CD19+
RTX   anti-CD22 RTX   anti-CD22
0.5 6   6   s
ur
fa
ce
 a
cc
es
si
bl
e 
m
Ab
s 
(%
)
0
20
40
60
80
100
IgD+ IgD-
* ns
Time (h)
RTX   anti-CD22 RTX   anti-CD22
nsns
NT anti-IgM F(ab')2
6   6   6   6   s
ur
fa
ce
 a
cc
es
si
bl
e 
m
Ab
s 
(%
)
D
A
C
Figure 6. Effect of IgD and B cell activation on the internalization of anti-CD20 monoclonal antibodies (mAb) in B cell subpopulations. A, Rit-
uximab (RTX) was internalized to a significantly lesser extent by postswitched (post-s) memory cells (IgD–CD271) than by the other B cell sub-
populations, both before and after blocking with AT10. A significantly greater percentage of glycosylated GA101 with an unmodified Fc portion
(GA101Gly) was accessible on postswitched cells than on naive (IgD1CD27–) or double-negative (DN; IgD–CD27–) cells before blocking with
AT10 and only on naive cells after blocking with AT10. Preswitched (pre-s) cells were defined as IgD1CD271 B cells. B, A greater percentage
of RTX was accessible on the surface of IgD– B cells than on IgD1 B cells. No such difference was noted for GA101Gly. C, Internalization of
RTX was not inhibited by B cell activation with anti–IgM F(ab0)2 in CD191 B cells as compared with no treatment (NT). D, A greater percent-
age of RTX was accessible at 6 hours in IgD1 B cells, but not IgD– B cells, from samples incubated with anti-IgM F(ab0)2 as compared with
untreated samples. No such difference was noted for anti-CD22 mAb. In A and B, each symbol represents an individual sample; horizontal lines
show the median. In C and D, each line represents an individual sample. *5P , 0.05; **5P , 0.005. NS5 not significant.
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We also examined differences in internalization
between B cell subpopulations based on the expression
of IgD (IgD1 or IgD–), CD27 (CD271 or CD27–), and
CD38 (CD38low or CD3811). Again, in samples incu-
bated with RTX, there was significantly greater internal-
ization of RTX in IgD1 B cells than IgD– B cells, and
internalization was inhibited by AT10 (Figure 6B). This
may be partly due to the differential expression of
FcgRIIb and IgD (Supplementary Figures 2A and B,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39167/abstract).
No such findings were observed in B cell subpopulations
based on the expression of CD27 (Supplementary Figure
3A, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39167/abstract)
or CD38 (Supplementary Figure 3B). In samples incubated
with GA101Gly, no differences were observed with any B
cell subpopulations. We found no differences in the inter-
nalization of anti-CD22 mAb between B cell subpopula-
tions (n5 3) (data not shown). Thus, internalization of type
I mAb, but not type II mAb or anti-CD22 mAb, was signifi-
cantly lower in postswitched cells and IgD–B cells overall.
It has previously been reported that the expression
of FcgRIIb differs between B cell subpopulations in SLE
patients (33) and may therefore account for the disparity
in internalization. We confirmed that the expression of
FcgRIIb varied between B cell subpopulations in SLE
(Supplementary Figure 2A, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39167/abstract), with naive cells, double-
negative cells,postswitched cells, preswitched cells. In
contrast to the expression of FcgRIIb, the expression of
IgD on naive cells was greater than that in preswitched
cells (Supplementary Figure 2B). This finding was espe-
cially of interest in conjunction with the finding that inter-
nalization of mAb was greatest in the IgD1 B cells rather
than the IgD– B cells.
Given that internalization of mAb was higher in
the IgD1 B cells and that the outcome of BCR engage-
ment leading to either signaling or internalization has
previously been shown to be mutually exclusive and
dependent on the phosphorylation of tyrosine-based
motifs (35), we investigated whether B cell activation
inhibited internalization of RTX or anti-CD22 mAb. Iso-
lated B cells were incubated with or without 25 mg/ml of
anti-IgM F(ab0)2 for 0.5 or 6 hours. Internalization of
RTX, but not anti-CD22 mAb, was inhibited by B cell
activation with anti-IgM F(ab0)2 only in IgD1 B cells
(P , 0.05), but not IgD2 B cells, at 6 hours (Figures 6C
and D). Taken together, these results suggest independent
roles for FcgRIIb and the BCR in regulating the internal-
ization of RTX, but not GA101Gly or anti-CD22 mAb.
DISCUSSION
Rituximab treatment was first used at our center for
the treatment of RA (36) and SLE (37). Although efficacy
was demonstrated in seropositive RA (38) and despite
encouraging results in several open studies (39), 2 random-
ized clinical trials failed to show efficacy in SLE (40,41). We
have previously discussed whether several factors, including
trial design, may have contributed to the apparent lack of
efficacy in these trials (42). A key factor is that rituximab
fails to induce complete depletion in some patients with RA
(3,43) and SLE (4), which is associated with a poor treat-
ment response.We have previously shown that serum rituxi-
mab levels vary remarkably in both RA and SLE patients,
are higher in RA patients than in SLE patients, and are
higher in patients with well-depleted B cells than in those
without, but only in RApatients and not SLE patients (44).
Together, these findings suggested disease-specific
mechanisms of resistance to depletion, in particular for
SLE, and enhancing depletion may improve clinical
response. Furthermore, a better understanding of resist-
ance mechanisms may guide selection of appropriate B
cell–depleting agents. Our goal in the present study was
thus to compare the in vitro efficiency of RTX and alter-
native CD20 mAb and to explore potential resistance
mechanisms in RA and SLE.
We used whole blood B cell–depletion assays to
compare the type I mAb RTX and ofatumumab with the
type II mAb tositumomab (B1) and GA101Gly and showed
that the type II mAb were significantly more effective at
depleting B cells from patients with RA and SLE. Owing
to its murine IgG2a isotype, tositumomab would be
expected to be less efficient at recruiting CDC and ADCC
in humans as compared with the human IgG1 isotype of
rituximab; however, the type II nature appears to offset
the murine isotype effect, resulting in superior cytotoxicity
to that of RTX in the whole blood B cell–depletion assay.
A wide variability in the efficiency of depletion was
observed in the case of RTX in SLE patients, which corre-
lated with the level of internalization. This suggested that
internalization of RTX is a probable “resistance mecha-
nism” in patients with SLE and may explain its variability
in depletion (45). The activity of the 2 types of mAb dem-
onstrated in vitro may not reflect their activity in vivo.
However, alterations of the immune system in patients
with SLE, such as defective phagocytosis (46) and natural
killer cell function (47), may explain why even type II anti-
CD20 mAb failed to achieve B cell depletion in SLE
patients that was comparable to that in RA patients and
healthy controls. Furthermore, type I CD20 mAb (RTX)
induces CDC, whereas type II mAb are poor inducers of
CDC (8), and thus, the efficiency of type I CD20mAbmay
be compromised in conditions with defects in complement
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function, such as SLE (48). We are currently investigating
this possibility.
The development of human antichimeric antibod-
ies is more common in SLE patients (2), and this limits
the repeated use of RTX. GA101, a fully humanized,
Fc-engineered type II CD20 mAb that has been shown to
achieve better patient outcomes than RTX in chronic lym-
phocytic leukemia (19), which is now a Food and Drug
Administration–approved indication (49), may potentially
overcome, at least in part, these resistance mechanisms.
Also under exploration for use in SLE are mAb
that target B cell surface proteins other than CD20,
including anti-CD19 (34) and anti-CD22 mAb (50),
which are aimed at depleting B cells and/or modulating
their function. We found a differential internalization of
these mAb in B cells from patients with SLE, with rapid
internalization of anti-CD22 mAb that was unaffected
by FcgRIIb and with variable internalization and regula-
tion of anti-CD19 mAb by FcgRIIb. Internalization of
mAb results in lower amounts of mAb on the target cell
surface being accessible to immune effector cells (22),
thereby compromising their cytotoxicity, particularly in
SLE, which showed rapid internalization of RTX.
Interestingly, internalization of RTX, but not anti-
CD22 mAb, was variable across B cell subpopulations,
being low in postswitched (IgD–CD271) memory cells
and IgD– cells, which suggests reduced intrinsic resistance
to depletion. Also, internalization of RTX, but not anti-
CD22 mAb, was independently inhibited both by blocking
of FcgRIIb and by B cell activation in IgD1 B cells. Taken
together, these results suggest that FcgRIIb and BCR acti-
vation influence the internalization of type I anti-CD20
mAb, but not anti-CD22 mAb. Thus, distinct mechanisms
operate to facilitate the internalization of different mAb.
The differences in internalization between antigen-specific
mAb may be related to the constitutive endocytosis of the
target antigen, as for CD22 (51), or to the redistribution of
CD20 into lipid rafts after incubation with RTX (22).
Knowledge of the factors that influence internalization of
mAb could be exploited to refine B cell–targeting strat-
egies in autoimmune diseases such as RA and SLE.
In conclusion, our results provide strong preclinical
evidence for considering the use of mechanistically differ-
ent type II CD20 mAb such as GA101 as alternative B
cell–depleting agents for the treatment of RA and SLE.
We have also identified distinct mechanisms of internaliza-
tion of rituximab and its regulation, which may explain the
variability in B cell depletion noted in patients with SLE.
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